CA3199760A1 - Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist - Google Patents

Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist

Info

Publication number
CA3199760A1
CA3199760A1 CA3199760A CA3199760A CA3199760A1 CA 3199760 A1 CA3199760 A1 CA 3199760A1 CA 3199760 A CA3199760 A CA 3199760A CA 3199760 A CA3199760 A CA 3199760A CA 3199760 A1 CA3199760 A1 CA 3199760A1
Authority
CA
Canada
Prior art keywords
sad
individual
compound
symptom
fear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3199760A
Other languages
English (en)
French (fr)
Inventor
Mihael Polymeropoulos
Yunsheng He
Christos POLYMEROPOULOS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of CA3199760A1 publication Critical patent/CA3199760A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CA3199760A 2020-11-25 2021-11-24 Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist Pending CA3199760A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063118121P 2020-11-25 2020-11-25
US202063118132P 2020-11-25 2020-11-25
US63/118,132 2020-11-25
US63/118,121 2020-11-25
US202163158449P 2021-03-09 2021-03-09
US63/158,449 2021-03-09
PCT/US2021/060720 WO2022115526A1 (en) 2020-11-25 2021-11-24 Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist

Publications (1)

Publication Number Publication Date
CA3199760A1 true CA3199760A1 (en) 2022-06-02

Family

ID=78957498

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3199760A Pending CA3199760A1 (en) 2020-11-25 2021-11-24 Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist

Country Status (8)

Country Link
US (1) US20230381169A1 (https=)
EP (1) EP4251158A1 (https=)
JP (1) JP2023553354A (https=)
KR (1) KR20230112622A (https=)
AU (1) AU2021387993A1 (https=)
CA (1) CA3199760A1 (https=)
MX (1) MX2023005895A (https=)
WO (1) WO2022115526A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
JP6263469B2 (ja) 2011-07-15 2018-01-17 ノバルティス アーゲー アザ二環式ジ−アリールエーテルの塩およびその製造方法またはその前駆体の製造方法
EP2742940B1 (en) * 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily

Also Published As

Publication number Publication date
AU2021387993A9 (en) 2024-02-08
JP2023553354A (ja) 2023-12-21
AU2021387993A1 (en) 2023-06-08
US20230381169A1 (en) 2023-11-30
EP4251158A1 (en) 2023-10-04
KR20230112622A (ko) 2023-07-27
WO2022115526A1 (en) 2022-06-02
MX2023005895A (es) 2023-06-06

Similar Documents

Publication Publication Date Title
JP2018518499A (ja) 神経学的疾患または障害を処置するためのｖｍａｔ２阻害剤
EA012036B1 (ru) Мемантин для лечения расстройств поведения детского возраста
US11826321B2 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
JP2022514194A (ja) 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール
CN104884053B (zh) 用于改善记忆表现的益智组合物
TWI784220B (zh) 腦性麻痺運動障礙之治療方法
US20240299375A1 (en) Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis
JP2009531431A (ja) 認知障害および他の障害の治療方法
TWI592156B (zh) 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
JP7822954B2 (ja) ダリドレキサントの医学的用途
CA3199760A1 (en) Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist
RU2840314C1 (ru) Лечение боязни публичного выступления агонистом альфа-7 никотинового ацетилхолинового рецептора
US20240197698A1 (en) Treatment of acute anxiety with an alpha-7 nicotinic acetylcholine receptor modulator
CN116761604A (zh) 用α-7烟碱型乙酰胆碱受体激动剂治疗当众讲话焦虑
CA3246418A1 (en) NEW USE OF PITOLISANT FOR THE TREATMENT OF SEVERE FATIGUE
TW202302109A (zh) 認知損傷之治療
US20210283075A1 (en) Methods of treating attention deficit hyperactivity disorder
TW202606707A (zh) 不具副作用之９－［４－（環己氧基）苯基］－７－甲基－３，４－二氫吡并［２，１－ｃ］［１，２，４］噻二－２，２－二氧化物投與方法
HK40112834A (zh) 用於痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗
US20200038415A1 (en) Aminosterol compositions and methods of using the same for treating erectile dysfunction
WO2012048871A1 (en) Memantine for improving cognitive performance in subjects
HK1157591A (en) Compositions and methods for extended therapy with aminopyridines
HK1184674A (en) Treatment for neurological and mental disorders
HK1184674B (en) Treatment for neurological and mental disorders

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241203

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241203

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241203

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251029

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251029

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251029

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251114

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251114

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251117

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20251117

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251117

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251117

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251117

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251118